Related Experiment Video

Updated: Feb 7, 2026

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]

Limei Yin1, You Lu1

  • 1Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|July 25, 2018
PubMed

Insights

MET 14 exon skipping alterations show promise as a biomarker for targeted therapies in non-small cell lung cancer (NSCLC). Further clinical data is needed to confirm the efficacy of MET inhibitors in NSCLC patients with this specific mutation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targeted therapy has revolutionized non-small cell lung cancer (NSCLC) treatment.
  • Mesenchymal to epithelial transition factor (MET) is an emerging molecular target in NSCLC, alongside EGFR and ALK.
  • MET 14 exon skipping alterations are increasingly recognized in NSCLC.

Purpose of the Study:

  • To review the current research on MET 14 exon skipping alterations in NSCLC.
  • To summarize the molecular mechanisms, clinicopathological features, and treatment strategies.
  • To discuss drug resistance mechanisms associated with MET alterations.

Main Methods:

  • Literature review of clinical trials and case reports.
  • Analysis of molecular mechanisms and clinicopathological data.
  • Synthesis of information on treatment strategies and resistance.

Main Results:

  • MET inhibitors show potential in treating NSCLC patients with MET 14 exon skipping alterations.
  • MET 14 exon skipping mutations may serve as a predictive biomarker for MET inhibitors.
  • Clinical data suggests a promising therapeutic prospect for MET-targeted agents.

Conclusions:

  • MET 14 exon skipping alterations represent a significant area of research in NSCLC.
  • Further clinical validation is required to confirm the biomarker status and efficacy of MET inhibitors.
  • Understanding resistance mechanisms is crucial for optimizing MET-targeted therapies.
Keywords:
CrizotinibLung neoplasmsMETTargeted therapyTyrosine kinase inhibitors

More Related Videos

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Mutations01:39

Mutations

Overview
94.6K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.2K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K